Analysis
Startup-on-startup M&A remains one of the more active corners of the market, with ultra-high-valuation unicorns leading acquisitions across AI, fintech and biotech, according to Crunchbase News.
The mechanics are straightforward and were common in the 2014-2015 and 2021 peaks: a company carrying a rich private valuation issues shares to buy a smaller company, spending currency it minted itself rather than cash it earned. When the acquirer's mark holds, everyone does well. When it does not, the selling founders discover they exchanged a real business for a position in someone else's cap table, several liquidation preferences deep.
“When it does not, the selling founders discover they exchanged a real business for a position in someone else's cap table, several liquidation preferences deep.”
What is different this cycle is the buyer profile. AI-native companies two or three years old are acquiring teams and products, and the strategic logic is usually talent and time rather than revenue -- buying a working inference-optimization team is faster than hiring one. Antitrust scrutiny of Big Tech acquisitions has also pushed some deal flow down-market, since a $200 million purchase by a private company attracts far less regulatory attention than the same asset going to a hyperscaler.
Crunchbase names Paper, the AI-native tutoring and education platform, among the unicorns actively rolling up smaller companies this cycle, alongside similarly-sized players in fintech and biotech tooling. The pattern repeats across categories: a company that raised at a nine- or ten-figure private mark uses its own stock as an acquisition currency the way a public acquirer would use cash, absorbing smaller teams before they need to raise another round in a tighter market. For the acquired company, it is often a better outcome than the alternative -- winding down or raising a bridge round at a down valuation -- even if the currency received is illiquid.
For early-stage funds, this is a genuinely useful development. A fund that owns 8% of a seed-stage company sold for $300 million in unicorn stock still faces the question of when that stock becomes cash, but a paper markup with a plausible path beats a company that quietly winds down. The discipline to insist on is cash or registration rights in the deal terms -- accepting private stock with no liquidity mechanism is how a good exit becomes a footnote in a fund's DPI story.
